Global Biosimilars Market Research Report; Latest Trends, Size, Share & Industry Analysis until 2025: Europe market is anticipated to lose its market share to North America

AnalystView Market Insights always aims at offering an in-depth and comprehensive analysis on different industry domains. This newly published market research report on the global biosimilars market is a significant part of AnalystView Market Insights’ machinery portfolio and represents detailed insights into this market space. The comprehensive study on biosimilars market provides market estimation for products and application segments. This comprehensive study reveals the market estimate numbers for different market segments. Along with that, the study covers qualitative insights, strategic benchmarking and thorough competitive landscaping in the report spreading over 150 pages. In total, the information contained in this report is intended to communicate a complete understanding of global biosimilars market through a series of easily digestible nuggets.

The global biosimilars market is expected to grow at growth rate of 35.7% to reach USD 61.82 billion by 2025.Biosimilars are the biologic pharmaceuticals which are similar to the reference biologic products. These drugs are similar to biological products which contains synthetically manufactured protein molecules. When the patent of brand drug is expired, manufacturers are planning to develop off-patent biologics like biosimilars that offer similar biological activity. The biosimilars industry offers various opportunities to the manufacturers owing to associated advantages.

As per the various research studies, biosimilars reduce drug development cost up to 20%-25% compared to the originator products owing to the reduced clinical trials. Thus, several companies such as Teva Pharmaceutical, Hospira, Inc., and Amgen are in constant efforts to develop biosimilar. For which, these companies are rigorously increasing their research and development expenses on clinical trials to introduce novel biosimilars. For example, Amgen has a strong product pipeline under biosimilar segment such as ABP 798 (biosimilar rituximab), ABP 710 (biosimilar infliximab), and ABP 215 (biosimilar bevacizumab). Furthermore, increasing incidences of chronic diseases coupled with large number of blockbuster biologics (e.g. Enbrel, and Remicade) going off patent support the industry growth significantly. However, strict regulations and high cost for R&D activities will hamper the market growth.

Request exclusive PDF sample copy of the report:
https://www.analystviewmarketinsights.com/request_sample/av134/

Key Takeaways:

• In terms of products, the industry is categorized as Recombinant Glycosylated Proteins and Recombinant Non-Glycosylated Proteins.
• Recombinant non-glycosylated proteins accounted for the highest share, i.e. 60.1% in 2016. This segment is further bifurcated into Human growth hormone, Lepirudin, Insulin, Interferons, and Granulocyte Colony-Stimulating Factor (G-CSF).
• Recombinant Glycosylated Proteins segment will provide overall market estimation for products such as factor VIIa, activated protein-c, tissue plasminogen activator, erythropoietin, monoclonal antibodies, and follitropin.
• In terms of application, oncology segment captured maximum share with 36.9% share in 2016. Increasing cancer incidences help the segment to grow consistently over the study period.
• In March 2015, U.S. FDA approved its first biosimilar named Zarxio (Filgrastim), and up till now, four biosimilars have been approved by US FDA. With a large number of biologics products expected to go off by 2020 in the U.S., the market for the U.S. seems to be more lucrative.
• Europe market is anticipated to lose its market share to North America with the entry of the United States in the biosimilars market
• Asia Pacific region is growing with a promising growth rate over the study period. India has been approving biosimilars at a rapid pace after its release of regulatory guidelines in 2012. India has a higher rate of acceptance for biosimilars and has approved more than 50 biosimilars till date.
• Companies namely Teva Pharmaceuticals, Sandoz AG, and Pfizer account for almost 80% of the industry share.
• However, it is estimated that these companies are projected to lose their market share to other major players such as Biocon and Amgen in the long run due to strong product pipeline.

Browse full research highlight with in-depth ToC on “Biosimilars Market, By Products, By Application and Geography – Analysis, Share, Trends, Size, & Forecast From 2014 – 2025” at
https://www.analystviewmarketinsights.com/report-highlight-biosimilars-market-134/

The scope of this report covers the market by its major segments, as follows:

MARKET, BY PRODUCT TYPES
1. Recombinant Glycosylated Proteins
2. Recombinant Non-Glycosylated Proteins

MARKET, BY APPLICATION
1. Oncology
2. Blood Disorders
3. Infectious Diseases
4. Autoimmune Diseases
5. Others

MARKET, BY REGION
1. North America
- U.S.
- Canada
2. Europe
- Germany
- France
- Rest of Europe
3. Asia Pacific
- India
- China
- Rest of APAC
4. Rest of the World
- Middle East and Africa
- Latin America

Key players profiled in this report with special attention on competitive landscape includes, (can be further customized to include additional 10 profiles):
1. Abbott Laboratories
2. Amgen, Inc.
3. AstraZeneca
4. Pfizer, Inc.
5. BIOCON Limited
6. Novartis AG
7. STADA
8. Teva Pharmaceuticals Inc.

Key Question Answered:
1. What are the key market trends, drivers, barriers, opportunities and recommendations?
2. What will the market size be from 2014 to 2025 and expected growth rate?
What is the revenue share of biosimilars market, by types, by brand, and by different geographies?
3. Who are the largest revenue contributor as well as fastest growing category for respective industry segments?
4. Who are the key vendors in Global Biosimilars Market space?
5. What are the strategies adopted by key vendors to expand their market presence?
6. What is the revenue share of key players operating in this market (2017)?

* Please note that preparing of customized report catering to a particular region or country is also possible within quicker timeframe as we follow bottom-up research methodology

Value Proposition:
• We are committed to provide valuable insights to our clients in order to help them take strategic decisions and in turn influencing revenue growth. The proposed study answers several important questions for stakeholders, primarily which industry segments to focus on in the next three to five years for prioritizing investments
• The proposed report presents a macro and micro-level outlook regarding the industry. Thus, it becomes easy for our clients to perceive the business landscape and take a glimpse of their own standing in it.
• A thorough analysis of relevant statistical data to estimate the market paradigms
• Exceptional understanding of the region and country-specific markets. The report will answer some of the toughest questions regarding the market shares, sizes, forecasts segmentations, and growth specific to the countries.
• Well-designed strategic framework analyzes the market movements including regional expansion, mergers & acquisitions, and new product developments

About Us
AnalystView Market Insights is a market research and consulting firm that adopts a proactive approach to provide the diverse need for accurate and precise market research, custom research, and consulting solutions across geographies and industry verticals. We strive to develop meaningful and evidence-based research data that helps our clients, empowering organizations and brands of all sizes with strategic analysis, accurate data, and consumer trends for various industries such as Healthcare, Bulk Chemicals, Semiconductors, Electronics, and Foods and Beverages.

Contact Us
Mr. Jose (Press & Marketing Manager)
Corporate Sales, USA
AnalystView Market Insights
Email: sales@analystviewmarketinsights.com
Tel: +91-757-498-5725 (Asia-Pacific Business Centre)
Web: www.analystviewmarketinsights.com

This release was published on openPR.